Microalbuminuria accounts for the increased vascular disease risk in diabetic patients with metabolic syndrome;La microalbuminuria explica el incremento de riesgo vascular en pacientes con diabetes y síndrome metabólico

Revista Espanola de Cardiologia

Volumn 60, Issue 11, 2007, Pages 1202-1205

  Gimeno Orna, José A ^a,b   Molinero Herguedas, Edmundo ^a   Lou Arnal, Luis M ^a   Boned Juliani, Beatriz ^a   Labrador Fuster, Tomás ^a   Guiu Campos, Miguel ^a  

^a Hospital de Alcañiz Alcañiz   (Spain)

^b NONE   (Spain)

Author keywords

Cardiovascular disease; Diabetes mellitus; Syndrome X

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT;

EID: 37349097071     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13111802     Document Type: Article

References (15)

1. Orozco-Beltrán D, Suárez-Fernández C, Serrano-Ríos M. Definición y concepto del síndrome metabólico. Diferencias y similitudes en el diagnóstico y la práctica clínica. Med Clin Monogr (Barc). 2006;7:2-7.
2. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care. 2005;28:1769-78.
3. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289-304.
4. Grundy SM. Does the metabolic syndrome exits? Diabetes Care. 2006;29:1689-92.
5. Kahn R. The metabolic syndrome (Emperor) wears no clothes. Diabetes Care. 2006;29:1693-6.
6. Gimeno Orna JA, Lou-Arnal LM, Molinero-Herguedas E, Boned Juliani B, Portilla-Cordoba D. Síndrome metabólico como marcador de riesgo cardiovascular en pacientes con diabetes tipo 2. Rev Esp Cardiol. 2004;57:507-13.
7. Alberti KG, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
8. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
9. Bonora E, Kiechl S, Willeit J, Oberhollonzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-9.
10. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21:52-8.
11. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes. Diabetes Care. 2004;27:2689-94.
12. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391-7.
13. Alegría E, Cordero A, Laclaustra M, Grima A, Leon M, Casasnovas JA, et al. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev Esp Cardiol. 2005;58:797-806.
14. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, Den Ottolander GJ. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non insulin dependent diabetes mellitus. Lancet. 1992;340:319-23.
15. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.